secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001193125-22-185580
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences receives FDA Fast Track for belzupacap sarotalocan in NMIBC; Phase 1 trial H2 2022
--------------------------------------------------------------------------------

- FDA granted Fast Track designation for belzupacap sarotalocan (AU-011) for treatment of Non-Muscle Invasive Bladder Cancer.
- NMIBC has no approved targeted therapies; high recurrence and progression often leading to cystectomy.
- Aura plans Phase 1 trial in NMIBC starting H2 2022, with initial data expected in 2023.
- AU-011 previously received Fast Track and Orphan Drug designations for choroidal melanoma, currently in Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522185580/0001193125-22-185580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522185580/d371151d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-185580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer